Although intended for the lungs, many drugs are not given via the airway because drug properties make it too difficult to formulate for direct to lung delivery.

Given systemically, these drugs often produce unwanted and potentially life-threatening side effects. To get around this, companies have tried to use microcapsules, carriers, and other agents to try to dose drugs direct to the lungs, but these other delivery agents often produce their own problems.

Using its proprietary technology, TFF can generate dry powder inhaler versions of these drugs using nothing but the drug itself and approved lung friendly ingredients. This means that drugs of all types – small molecules, biologics, even combinations – can be dosed direct to the lungs with few, if any, side effects.

Management

Glenn Mattes, TFF Pharmaceuticals Chief Executive Officer
Glenn Mattes, TFF Pharmaceuticals Chief Executive Officer

Chief Executive Officer

Glenn Mattes

Mr. Mattes is Chief Executive Officer of TFF Pharmaceuticals. He joined the company May 2018, bringing more than 30 years of business leadership, global therapeutics development expertise, and executive management experience to his role with the company.

In his capacity as Chief Executive Officer Mr. Mattes or Glenn, has oversight of the direction and strategy at TFF Pharmaceuticals, facilitating company activity in business development, marketing, investor relations, commercialization alliances and channels, and management support. He works to share the company’s vision and strategy with partners, investors and shareholders.

Mr. Mattes serves on the Boards of Advantagene, Inc., Deck Therapeutics, Cornovus, Inc. and CannaMetrix. He is an advisor to the Gores Group and Clayton Foundation for Research, and served as an advisor to PTV Healthcare Capital. He is also an Operating Partner of Revival Healthcare.

Web-Brian_Windsor-9645-Edit

Chief Scientific Officer

Brian Windsor, Ph.D

Dr. Windsor is currently President and CEO of Lung Therapeutics, a specialty pharmaceutical company focused on novel therapeutics to address unmet needs in lung injury and disease. He has spent the last 18 years in the formation and management of life science-based technology ventures and has led technology development and licensing to major pharmaceutical firms as well as public and private biotechnology companies.

Dr. Windsor brings recent leadership experience in pharmaceutical drug development and most recently served as President of Enavail, LLC, a specialty pharmaceutical manufacturing company developing unique formulations for superior drug performance. While at Enavail, Dr. Windsor oversaw all aspects of pharmaceutical drug development, including drug selection, regulatory strategy, preclinical and clinical strategy, GMP manufacturing, and strategic partnering for pharma products.

Kirk Coleman

Chief Financial Officer

Kirk Coleman

Mr. Coleman has served as our Chief Financial Officer since January 2018. Since 2012, Mr. Coleman has also served as an executive officer of Steelhead Capital Management, LLC and Bios Partners, LP, a venture capital firm focused on investment in early-stage and growth-stage biotech and medical device companies.

From 1998 to 2008, Mr. Coleman was Treasurer for EFO Holdings, LP, a family office. Mr. Coleman has over 20 years of experience in venture capital investments. Mr. Coleman received a BBA in Accounting from Texas Christian University in 1995.

Board of Directors

Glenn Mattes, TFF Pharmaceuticals Chief Executive Officer

CEO & Board Member

Glenn Mattes
Web-Brian_Windsor-9645-Edit

CSO & Board Member

Brian Windsor, Ph.D
Web-Aaron_Fletcher-9615-Edit

Board Chairman

Aaron Fletcher, Ph.D.
Web-Bob_Mills-9608-Edit

Board Member

Bob Mills
Harlan F. Weisman Headshot-720

Board Member

Harlan F. Weisman
Stephen Rocamboli

Board Member

Stephen Rocamboli
Share this page on social media:
Share on Twitter
Share on Facebook
Share on LinkedIn
Share on Google Plus
Share on Pinterest
Share on Email

Contact Us

Let us know if you would like more information about TFF
  • This field is for validation purposes and should be left unchanged.